Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Canceled)

2-18. (Canceled)

19. (currently amended) A recombinant adenovirus vector for expressing an interferon-α polypeptide in a mammalian cell, ~~comprising~~ wherein said vector comprises a nucleic acid segment encoding an interferon-α polypeptide, the nucleic acid segment being operatively linked to a promoter specific for a tissue of interest, wherein the nucleic acid segment encoding the interferon-α polypeptide lacks a secretion leader sequence.

20. (Original) The vector of claim 19, wherein the interferon-α polypeptide is interferon-α2b.

21. (Original) The vector of claim 19, wherein the interferon-α polypeptide is interferon-α2-α1.

22. (Original) The vector of claim 19, wherein the interferon-α polypeptide is a consensus interferon-α polypeptide.

23. (Original) The vector of claim 20, wherein the promoter is a liver specific promoter.

24. (Original) The vector of claim 20, wherein the promoter is the AFP promoter.

25. (Canceled)

26. (Currently amended) The vector of claim **[[25]]** 19 wherein the adenoviral vector is replication deficient.

27. (Original) The vector of claim 26 which is rAdNSI-α2b.

28. (Original) The vector of claim 25 wherein the adenoviral vector is replication competent.

29. (Original) The vector of claim 28 wherein the endogenous adenoviral EI promoter is replaced with the AFP promoter.

30-34. (Canceled)

35. (Canceled)

36-39. (Canceled)

40. (New) A mammalian cell comprising the vector of any of claims 19-29, wherein said vector is extrachromosomal, and wherein expression of the interferon-α polypeptide encoded by said vector reduces the rate of proliferation of said cell relative to similar mammalian cells which do not comprise said vector.

41. (New) The mammalian cell of claim 41, wherein said cell is a cancer cell.

42. (New) The mammalian cell of claim 42, wherein said cell is a liver cancer cell.